 |
|
- |
|
|
-
|
|
|
Focus on Safety:
New Publications Highlight LifeNet Health’s Life Saving Work in Neurosurgery
LifeNet Health is pleased to announce two recent publications that examine the innovative OsteoCleanse™ autograft cleaning service for the treatment of infected or contaminated cranial bone flaps. Both case studies attest to the effectiveness of the OsetoCleanse autograft cleaning service. OsteoCleanse™is one of several advanced technology platforms that LifeNet Health utilizes to help restore health. Thousands of decompressive craniectomies are performed each year, often as the result of traumatic brain injuries (TBIs). Using OsteoCleanse, the resultant autografts are placed in a custom container, shipped to LifeNet Health, disinfected, labeled, and stored until re-implantation. OsteoCleanse is the first process of its kind specifically designed for autologous tissue and is based on LifeNet Health’s patented allograft treatment technologies which have been used since 1995 to clean, disinfect, and sterilize allograft tissue to remove risk of disease transmission. Read more…
|
|
|
Focus on Quality:
Recovery Biopsy Procedure Enhances Safety, Increases Donations
The American Association of Tissue Banks accepted a LifeNet Health study for publishing that examines the effect of recovery biopsy in determining donor eligibility and suitability. The study will be presented during the AATB 34th Annual Meeting, September 10-14 in National Harbor, Maryland. The findings indicate LifeNet Health’s recovery biopsy procedure is an integral safety strategy that increases the gift of donation and prevents unnecessary deferral or discard of donor tissue. Read more…
|
|
Focus on Service:
Customer Survey Reveals High Satisfaction with LifeNet Health Services
In April 2010, LifeNet Health commissioned Issues & Answers Network, Inc., to conduct a market research survey to measure customer satisfaction with the LifeNet Health Client Services Department. The survey included interviews with 94 customers conducted via telephone or online. Overall, the interviewed clients reported high satisfaction with LifeNet Health Client Services.
Read more...
|
|
Focus on Innovation:
PAD™ Technology Achieves Optimal Osteoinductivity
Achieving the optimal residual calcium level in critical to improving clinical outcomes. PAD™ is a patented allograft bio-implant demineralization technology that manages the demineralization process to yield an optimal residual calcium level between 1-4%. With PAD technology, an optimal residual calcium level of 1-4% is achieved, proteins are exposed and osteoinductivity is increased.
Read more… |
|
FACTOIDS:
|
